John Libbey Eurotext

European Journal of Dermatology


Hidradenitis suppurativa and adalimumab in the COVID-19 era Volume 30, numéro 6, November-December 2020

1 Dermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
2 Department of Physiopathology and Transplantation, Università degli Studi di Milano, Milan, Italy
3 Department of Medical Surgical and Health Sciences, University of Trieste, Trieste, Italy
4 Department of Medical Sciences, University of Turin, Turin, Italy
5 Department of Dermatology, University of Naples Federico II, Naples, Italy
6 Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
7 Dermatology Clinic, University of Catania, Catania, Italy
8 Dermatology Unit, Department of Surgery, Misericordia Hospital, Grosseto, Italy
9 Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy
10 Department of Dermatology, University of Pisa, Pisa, Italy
11 Department of Dermatology, University of Rome ’Tor Vergata’, Rome, Italy
12 First Dermatology Clinic and Clinical Epidemiology Unit, Istituto Dermopatico dell’Immacolata, IDI-IRCCS, Rome, Italy
13 Dermatological Clinic Department of Clinical and Molecular Sciences, Polytechnic University of the Marche Region, Ancona, Italy
14 Department Health Science Section of Dermatology, University of Florence, Florence, Italy
15 Unit of Dermatology, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy
16 Dermatologic Clinic, Department of Internal Medicine and Medical Specialties, ’La Sapienza’ University, Rome, Italy
17 Department of Clinical and Experimental Medicine, Section of Dermatology, University of Messina, Messina, Italy
18 Department of Medical Sciences, Section of Dermatology, University of Ferrara, Ferrara, Italy
19 Dermatology Section, Department of Medicine, University of Perugia, Perugia, Italy
20 Dermatology Unit, Ospedale Santa Chiara, Trento, Italy
21 Department of Dermatology, ASST Spedali Civili di Brescia, Brescia, Italy
22 Institute of Dermatology, Università Cattolica - Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy

A general concern about a potentially higher risk of COVID-19 among patients with inflammatory skin diseases, such as hidradenitis suppurativa, under treatment with biologics has promoted a number of reports in the scientific literature [1]. Recently, Blaszczak [2] found only a modestly increased risk of infections in HS patients treated with adalimumab versus those under placebo based on a review of the data published for PIONEER I and II trials [3]. Real-life data on COVID-19 risk in HS patients [...]